CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Incyte CORP (INCY) / povorcitinib
Forward catalyst · INCY

povorcitinib

Sponsor Incyte CORP · listed as INCY

READOUT Phase 3 Confidence: medium Source: clinicaltrials

povorcitinib is a clinical-stage drug asset sponsored by Incyte CORP, listed as INCY. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 26, 2026 (day precision, medium confidence), tied to trial NCT06212999. The asset is in Phase 3 and currently active not recruiting, studied in Hidradenitis Suppurativa (HS). It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-12-26
As disclosedDec 26, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06212999
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorIncyte Corporation
Listed asINCY
Condition(s)Hidradenitis Suppurativa (HS)
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More INCY catalysts